Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference
28 November 2022 - 1:00PM
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology
company advancing new treatments for patients suffering from
serious diseases underserved by current therapies, today announced
that senior management will participate in the 5th Annual Evercore
ISI HealthCONx Conference on Thursday, December 1, 2022.
Evercore ISI HealthCONx
Conference |
Format:
|
Fireside
Chat |
Date: |
December 1, 2022 |
Time: |
10:30 a.m. ET |
The live webcast of the fireside chat will be accessible under
"Events and Presentations” within “News and Events” on the
Investors section of the Viridian website at
viridiantherapeutics.com. A replay of the webcast will be available
on the Company’s website after the event.
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing
new treatments for patients suffering from serious diseases
underserved by current therapies. Viridian’s most advanced program,
VRDN-001, is a differentiated monoclonal antibody targeting
insulin-like growth factor-1 receptor (IGF-1R), a clinically and
commercially validated target for the treatment of thyroid eye
disease (TED). VRDN-002 is a distinct anti-IGF-1R antibody and
incorporates half-life extension technology. VRDN-003 is an
extended half-life version of VRDN-001. Both VRDN-002 and VRDN-003
are designed for administration as convenient, low-volume,
subcutaneous injections. TED is a debilitating autoimmune
disease that causes inflammation and fibrosis within the orbit of
the eye which can cause double vision, pain, and potential
blindness. Viridian is based
in Waltham, Massachusetts.
Investor and Media Contact:Todd JamesViridian
Therapeutics, Inc.Senior Vice President, Corporate Affairs and
Investor RelationsIR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024